Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Medtronic
QuintilesIMS
Cipla
Citi
Healthtrust
McKinsey
Cerilliant

Generated: June 18, 2018

DrugPatentWatch Database Preview

OMNARIS Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Omnaris patents expire, and when can generic versions of Omnaris launch?

Omnaris is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-six patent family members in forty-three countries.

The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ciclesonide profile page.
Summary for OMNARIS
Drug patent expirations by year for OMNARIS
Synonyms for OMNARIS
(11?,16?)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione
(11?,16?)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione
(11|A,16|A)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
126544-47-6
141845-82-1
2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-
2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-CYCLOHEXYL-11-HYDROXY-9,13-DIMETHYL-16-OXO-5,7-DIOXAPENTACYCLO[10.8.0.0(2),?.0?,?.0(1)(3),(1)?]ICOSA-14,17-DIEN-8-YL]-2-OXOETHYL 2-METHYLPROPANOATE
2-oxoethyl isobutyrate
2H-Naphth (2',1':4,5) indeno (1,2-d) (1,3) dioxole, pregna-1,4-diene-3,20-dione deriv.
544C476
AC-1330
AKOS015994702
Alvesco
Alvesco (TN)
Alvesco HFA
Alvesco, Ciclesonide
AN-15021
B-9207-015
BC220461
BTR-15
BTR-15K
BY-9010
BYK-20426
C-23151
C32H44O7
CAS-141845-82-1
CC-25775
CHEBI:31397
CHEMBL2040682
Ciclesonide
Ciclesonide (JAN/USAN/INN)
Ciclesonide [INN]
Ciclesonide [USAN:INN]
CS-2867
D01703
D0K7HU
DB01410
DR003211
DSSTox_CID_26659
DSSTox_GSID_46659
DSSTox_RID_81802
DTXSID9046659
el-87-6
GTPL7469
HY-B0625
KS-1165
LS-186047
LUKZNWIVRBCLON-GXOBDPJESA-N
MolPort-005-940-705
NCGC00167484-01
NCGC00167972-01
O945
Omnair
Omnaris (TN)
Omnaris HFA
Omniair (TN)
Osonase
Osonide
PL018866
Pregna-1,4-diene-3,20-dione, 16,17-(((R)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha)-
Pregna-1,4-diene-3,20-dione, 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha(R))-
RPR 251526
RPR-251526
RPR251526
s4646
S59502J185
SCHEMBL3688
SR-01000942227
SR-01000942227-1
TBN-15
Tox21_112486
UNII-S59502J185
Zetonna
ZINC3915154

US Patents and Regulatory Information for OMNARIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astrazeneca Pharms OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astrazeneca Pharms OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for OMNARIS
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2012-02-13

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Colorcon
Covington
Cipla
Accenture
Dow
Medtronic
Fuji
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.